July 31, 2024 – Toronto, Canada: Canurta Therapeutics is pleased to announce the granting of its first US patent for the company’s innovative hemp polyphenol extraction process. This significant development validates the novelty, inventiveness, and commercial applicability of Canurta’s cutting-edge technology, as recognized by the US Patent and Trademark Office.
The granted patent makes Canurta the first company in the United States to hold patents for novel processes to obtain purified and enriched cannflavins, hemp polyphenols, and other valuable molecules. Using specialized resins to capture these compounds, the newly patented method produces an innovative extract rich in bioactive flavonoids and bibenzyls, while being free from cannabinoids, making them ideal for use in pharmaceutical, and natural health products. This foundational patent not only underscores the company’s pioneering efforts but also sets the stage for the approval of other filed patents that further enhance Canurta’s proprietary technology.
The recent news of the rescheduling of cannabis from Schedule I to III in the US signifies a pivotal shift in the regulatory landscape, enabling greater exploration and utilization of cannabis-derived ingredients for medical and pharmaceutical purposes. Canurta’s patented technology is particularly timely and advantageous, aligning with the evolving legal framework and increasing demand for high-quality, naturally derived cannabis compounds.
As a Canadian-based biotechnology company, Canurta is strategically positioned to leverage this patent in expanding its operations and establishing robust business development relationships. This patent not only strengthens Canurta’s intellectual property portfolio but also enhances its ability to produce exclusive products, driving growth and innovation in the cannabis and biotechnology sectors.
The Importance of Cannflavins at Canurta Therapeutics
Cannflavins are a critical focus at Canurta due to their unique anti-inflammatory and therapeutic potential. Our research has demonstrated the potential of cannflavins in various health applications, making them a cornerstone of our innovation strategy.
For more detailed insights into the activity and potential of cannflavins, explore the following articles:
US patent US12011471B2 has been exclusively licensed to Canurta Inc from Atlas365 and all rights to the patent are owned outright by Canurta. Atlas365 is Akeem Gardner’s holding company. For additional details on the licensing agreement please contact investors@canurta.com
Comments